Melphalan monitoring during hyperthermic perfusion of isolated limb for melanoma: Pharmacokinetic study and 99mTc-albumin microcolloid technique

L. Cattel, E. Buffa, M. De Simone, P. Cesana, S. Novello, F. Dosio, M. Ceruti

Research output: Contribution to journalArticle

Abstract

Background: The kinetics of melphalan leakage from extracorporeal fluid to the peripheral blood was studied in ten patients undergoing hyperthomic isolation perfusion of the lower limbs as an adjuvant treatment in high-risk melanoma. Materials and Methods: Systemic leakage was monitored by a new technique using 99mTc-albumin microcolloid. Serial samples were drawn from a peripheral vein and from the perfusion circuit during surgical treatment and analysed by HPLC. Results: The leakage measured with 99mTc-albumin microcolloid ranged from 1.5 to 18 %/h (mean 8 %/h). The average concentrations in the perfusate were 200-300-fold those found in the systemic circulation. A good correlation (R=0.945) was obtained between systemic AUC (0 to 1 hour) and leakage measured through the 99mTc procedure. Negligible toxicity was found and the survival rate yielded 92% of objective response. Conclusion: By studying the pharmacokinetic data of melphalan in the circuit and in the systemic circulation, we were able to validate the 99mTc procedure used during clinical perfusion. Moreover, considering the efficiency of the system as well as the minimum toxicity and the high survival rate, a reduction of perfusion time may be considered.

Original languageEnglish
Pages (from-to)2243-2248
Number of pages6
JournalAnticancer Research
Volume21
Issue number3 C
Publication statusPublished - 2001

Fingerprint

Melphalan
Albumins
Melanoma
Extremities
Pharmacokinetics
Perfusion
Survival Rate
Area Under Curve
Lower Extremity
Veins
High Pressure Liquid Chromatography
Therapeutics

Keywords

  • 99m Tc
  • Melanoma
  • Melphalan
  • Pharmacokinetics
  • Regional chemotherapy

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Melphalan monitoring during hyperthermic perfusion of isolated limb for melanoma : Pharmacokinetic study and 99mTc-albumin microcolloid technique. / Cattel, L.; Buffa, E.; De Simone, M.; Cesana, P.; Novello, S.; Dosio, F.; Ceruti, M.

In: Anticancer Research, Vol. 21, No. 3 C, 2001, p. 2243-2248.

Research output: Contribution to journalArticle

Cattel, L. ; Buffa, E. ; De Simone, M. ; Cesana, P. ; Novello, S. ; Dosio, F. ; Ceruti, M. / Melphalan monitoring during hyperthermic perfusion of isolated limb for melanoma : Pharmacokinetic study and 99mTc-albumin microcolloid technique. In: Anticancer Research. 2001 ; Vol. 21, No. 3 C. pp. 2243-2248.
@article{39e78e7acc9347bf9ec030bce47a1eaf,
title = "Melphalan monitoring during hyperthermic perfusion of isolated limb for melanoma: Pharmacokinetic study and 99mTc-albumin microcolloid technique",
abstract = "Background: The kinetics of melphalan leakage from extracorporeal fluid to the peripheral blood was studied in ten patients undergoing hyperthomic isolation perfusion of the lower limbs as an adjuvant treatment in high-risk melanoma. Materials and Methods: Systemic leakage was monitored by a new technique using 99mTc-albumin microcolloid. Serial samples were drawn from a peripheral vein and from the perfusion circuit during surgical treatment and analysed by HPLC. Results: The leakage measured with 99mTc-albumin microcolloid ranged from 1.5 to 18 {\%}/h (mean 8 {\%}/h). The average concentrations in the perfusate were 200-300-fold those found in the systemic circulation. A good correlation (R=0.945) was obtained between systemic AUC (0 to 1 hour) and leakage measured through the 99mTc procedure. Negligible toxicity was found and the survival rate yielded 92{\%} of objective response. Conclusion: By studying the pharmacokinetic data of melphalan in the circuit and in the systemic circulation, we were able to validate the 99mTc procedure used during clinical perfusion. Moreover, considering the efficiency of the system as well as the minimum toxicity and the high survival rate, a reduction of perfusion time may be considered.",
keywords = "99m Tc, Melanoma, Melphalan, Pharmacokinetics, Regional chemotherapy",
author = "L. Cattel and E. Buffa and {De Simone}, M. and P. Cesana and S. Novello and F. Dosio and M. Ceruti",
year = "2001",
language = "English",
volume = "21",
pages = "2243--2248",
journal = "Anticancer Research",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "3 C",

}

TY - JOUR

T1 - Melphalan monitoring during hyperthermic perfusion of isolated limb for melanoma

T2 - Pharmacokinetic study and 99mTc-albumin microcolloid technique

AU - Cattel, L.

AU - Buffa, E.

AU - De Simone, M.

AU - Cesana, P.

AU - Novello, S.

AU - Dosio, F.

AU - Ceruti, M.

PY - 2001

Y1 - 2001

N2 - Background: The kinetics of melphalan leakage from extracorporeal fluid to the peripheral blood was studied in ten patients undergoing hyperthomic isolation perfusion of the lower limbs as an adjuvant treatment in high-risk melanoma. Materials and Methods: Systemic leakage was monitored by a new technique using 99mTc-albumin microcolloid. Serial samples were drawn from a peripheral vein and from the perfusion circuit during surgical treatment and analysed by HPLC. Results: The leakage measured with 99mTc-albumin microcolloid ranged from 1.5 to 18 %/h (mean 8 %/h). The average concentrations in the perfusate were 200-300-fold those found in the systemic circulation. A good correlation (R=0.945) was obtained between systemic AUC (0 to 1 hour) and leakage measured through the 99mTc procedure. Negligible toxicity was found and the survival rate yielded 92% of objective response. Conclusion: By studying the pharmacokinetic data of melphalan in the circuit and in the systemic circulation, we were able to validate the 99mTc procedure used during clinical perfusion. Moreover, considering the efficiency of the system as well as the minimum toxicity and the high survival rate, a reduction of perfusion time may be considered.

AB - Background: The kinetics of melphalan leakage from extracorporeal fluid to the peripheral blood was studied in ten patients undergoing hyperthomic isolation perfusion of the lower limbs as an adjuvant treatment in high-risk melanoma. Materials and Methods: Systemic leakage was monitored by a new technique using 99mTc-albumin microcolloid. Serial samples were drawn from a peripheral vein and from the perfusion circuit during surgical treatment and analysed by HPLC. Results: The leakage measured with 99mTc-albumin microcolloid ranged from 1.5 to 18 %/h (mean 8 %/h). The average concentrations in the perfusate were 200-300-fold those found in the systemic circulation. A good correlation (R=0.945) was obtained between systemic AUC (0 to 1 hour) and leakage measured through the 99mTc procedure. Negligible toxicity was found and the survival rate yielded 92% of objective response. Conclusion: By studying the pharmacokinetic data of melphalan in the circuit and in the systemic circulation, we were able to validate the 99mTc procedure used during clinical perfusion. Moreover, considering the efficiency of the system as well as the minimum toxicity and the high survival rate, a reduction of perfusion time may be considered.

KW - 99m Tc

KW - Melanoma

KW - Melphalan

KW - Pharmacokinetics

KW - Regional chemotherapy

UR - http://www.scopus.com/inward/record.url?scp=0034902285&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034902285&partnerID=8YFLogxK

M3 - Article

C2 - 11501854

AN - SCOPUS:0034902285

VL - 21

SP - 2243

EP - 2248

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

IS - 3 C

ER -